INFLUENCE OF DOXORUBICIN ON ELECTRICAL ACTIVITY OF THE MYOCARDIUM AND LEFT VENTRICULAR FUNCTION DURING TREATMENT OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA

J. kolarović ,
J. kolarović

Institute for Child and Youth Health Care of Vojvodina , Novi Sad , Serbia

N. Konstantinidis ,
N. Konstantinidis

Institute for Child and Youth Health Care of Vojvodina , Novi Sad , Serbia

Lj. Milić-Georgijević ,
Lj. Milić-Georgijević

Institute for Child and Youth Health Care of Vojvodina , Novi Sad , Serbia

N. Kaćanski ,
N. Kaćanski

Institute for Child and Youth Health Care of Vojvodina , Novi Sad , Serbia

G. Novović
G. Novović

Institute for Child and Youth Health Care of Vojvodina , Novi Sad , Serbia

Published: 01.12.2009.

Volume 37, Issue 2 (2009)

pp. 9-12;

https://doi.org/10.70949/pramed200902288K

Abstract

Doxorubicin is the most frequently used anthracycline antibiotic that expresses significant toxicity. Among all side  effects, hematological are the most common, while cardiac side effects are the most serious and the most important. The aim of this study was to investigate whether doxorubicin containing combined chemotherapy used in treatment of childhood acute lymphoblastic leukemia (ALL), influences electrical activity of the myocardium and left ventricular function in affected children. Experimental group consisted of 20 children with newly diagnosed ALL treated according to protocol YU ALL 95, while the control group consisted of 20 healthy children. Electrocardiograms (ECG) at rest were taken and analyzed, and corrected QT intervals (QTc) calculated. All children had echocardiograms (ECHO) including fractional shortening (FS) and ejection fraction (EF). Electrocardiograms, FS and EF were normal in all subjects, and were similar in both groups.

Keywords

References

1.
Sallan SE, Clavel LA. Cardiac effects of anthracyclines used in the treatment of childhood acute lymphoblastic leukemia: A 10-year experience. Sem Oncol. 11:19–21.
2.
Swerdlow AJ, Higgins CD, Smith P, Cunningham D, Hancock BW, Horwich A, et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: A collaborative British cohort study. J Natl Cancer Inst. 99:206–14.
3.
Schrappe M. Improved outcome in childhood ALL despite reduced use of anthracyclines and of cranial therapy: Results of trial ALL-BMF 90. Blood. 95:3310–5.
4.
Cvetkoviæ P. Standardi za praæenja bolesnika sa terapijom antraciklinima. Bilt Hematol. 23(3):156–8.
5.
Pudil R, Horacek JM, Strasova SA. Monitoring of the very early changes of left ventricular diastolic function in patients with acute leukemia treated with anthracyclines. Exp Oncol. 30:160–2.

Citation

Copyright

Article metrics

Google scholar: See link

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Most read articles

Indexed by